For further information, contact:Janette CiborowskiEnterprise CommunicationsNVIDIA Corporation+1-734-330-8817jciborowski@nvidia.com Certain statements in this press release including, but not limited to, statements as to: the benefits, impact, availability, and performance of NVIDIA’s products, services, and technologies, including NVIDIA AI Foundry, NVIDIA NIM microservices, NVIDIA Blueprints, NVIDIA RAPIDS, NVIDIA AI Enterprise software platform, NVIDIA BioNeMo, NVIDIA MONAI, NVIDIA DGX B200 systems, NVIDIA Blackwell architecture, and NVIDIA DGX Cloud; NVIDIA’s partnership and collaboration with third parties, and the benefit and impact thereof; third parties adopting NVIDIA’s products and technologies, the benefits and impact thereof, and the features and performance of their offerings; and the combination of NVIDIA’s AI and accelerated computing capabilities with the expertise of industry leaders being poised to usher in a new era of medical and biological innovation and improve patient outcomes worldwide are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations.
"The combination of NVIDIA’s AI and accelerated computing capabilities with the expertise of industry leaders is poised to usher in a new era of medical and biological innovation and improve patient outcomes worldwide.” AI Foundry Services Boost Drug and Medical Device DevelopmentIQVIA — a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries — is using the NVIDIA AI Foundry service to build custom foundation models on its more than 64 petabytes of information, coupled with its deep domain expertise.
Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q.
The story "NVIDIA Partners With Industry Leaders to Advance Genomics, Drug Discovery and Healthcare" has 1544 words across 40 sentences, which will take approximately 7 - 13 minutes for the average person to read.
Which news outlet covered this story?
The story "NVIDIA Partners With Industry Leaders to Advance Genomics, Drug Discovery and Healthcare" was covered 1 weeks ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 25 news stories per day.
It's most recent story was published 8 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
